Substance / Medication

3,4-diaminopyridine

Overview

Active Ingredient
amifampridine
RxNorm CUI
2106338

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.
Sanders Donald B, Juel Vern C, Harati Yadollah et al. · Muscle Nerve · 2018
PMID: 29280483RCTFull text (PMC)
No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study.
Lorenz D, Hagen K, Ufer M et al. · Neurology · 2006
PMID: 16769957RCT
Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.
Thakkar Nilay, Guptill Jeffrey T, Aleš Kathy et al. · CPT Pharmacometrics Syst Pharmacol · 2017
PMID: 28623849TrialFull text (PMC)
Pharmacokinetics and safety of 3,4-diaminopyridine base in healthy Japanese volunteers.
Ishida Natsuko, Kobayashi Erina, Kondo Yuya et al. · Int J Clin Pharmacol Ther · 2015
PMID: 26152130Trial
3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study.
Flet Laurent, Polard Elisabeth, Guillard Olivia et al. · J Neurol · 2010
PMID: 20058019Trial
Treatment of the gravity dependence of downbeat nystagmus with 3,4-diaminopyridine.
Sprenger A, Rambold H, Sander T et al. · Neurology · 2006
PMID: 16966567Trial
Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine.
Mainero C, Inghilleri M, Pantano P et al. · Neurology · 2004
PMID: 15184612Trial
Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study.
Strupp M, Schüler O, Krafczyk S et al. · Neurology · 2003
PMID: 12874393Trial
A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
Sanders D B, Massey J M, Sanders L L et al. · Neurology · 2000
PMID: 10680790Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Amifampridine (substance)
SNOMED CT
422654000
UMLS CUI
C0046948
RxNorm CUI
2106338

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

3,4-diaminopyridine: Uses, Evidence & Side Effects | Ltrl